小剂量甲泼尼龙琥珀酸钠治疗毛细支气管炎的疗效观察被引量：5

下载PDF

导出

摘要目的：观察甲泼尼龙琥珀酸钠治疗小儿毛细支气管炎的疗效。方法58例我科确诊为毛细支气管炎的患儿按就诊先后随机抽签分为治疗组28例和对照组30例，2组患儿在综合治疗的基础上，对照组给予琥珀酸氢化可的松5mg·kg-1·次-1，2次/d静脉滴注；治疗组给予甲泼尼龙1mg·kg-1·次-1，2次/d静脉滴注，疗程3~5d。结果治疗组总有效率为96.4％明显高于对照组的90.0％，差异有统计学意义（ P＜0.05）；治疗组主要症状、体征缓解及住院时间明显短与对照组，差异有统计学意义（P＜0.05）。结论剂量甲泼尼龙琥珀酸钠治疗毛细支气管炎疗效明显优于琥珀酸氢化可的松。

作者周进柯杰

机构地区安徽省霍邱县第一人民医院儿科

出处《临床合理用药杂志》 2014年第17期43-44,共2页 Chinese Journal of Clinical Rational Drug Use

关键词甲泼尼龙琥珀酸钠毛细支气管炎琥珀酸氢化可的松

分类号 R725.6 [医药卫生—儿科]

引文网络
相关文献

参考文献7

1谢志才.毛细支气管炎患儿临床严重程度与哮喘发生的相关因素分析[J].中国妇幼保健,2010,25(21):2986-2987. 被引量：15
2American Academy of pediatrics. Guideline or the diagnosis and treat- ment of bronchiolitis [ J ]. pediatrics,2006,118 (4) : 1774.
3胡亚美,江载芳.诸福棠用儿科学[M].7版.北京:人民卫生出版社,2002:1199.
4邓继岿,郑跃杰,袁雄伟.布地奈德吸入与地塞米松静滴治疗婴儿毛细支气管炎的疗效比较[J].中国实用儿科杂志,2004,19(6):371-371. 被引量：51
5董晓艳,鲍一笑,吕婕,张廷熹.IL-13基因多态性与RSV感染后婴幼儿喘息及哮喘关系的研究[J].临床儿科杂志,2009,27(6):562-565. 被引量：13
6Legg JP,Hussain IR,Warner JA,et al. Type 1 and type 2 cytokine im- balance in acute respiratory syncytial virus bronchiolitis[ J ]. Am J Respir Crit Care Med,2003,168(6) :633 -639.
7李兰,王智斌,李敏,张剑波,陈昌辉,李波,吉德平.呼吸道合胞病毒毛细支气管炎患儿T细胞亚群的变化及其临床意义[J].四川医学,2005,26(3):332-333. 被引量：3

二级参考文献27

1Vladich FD, Brazille SM, Stern D, et ol. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation [J]. J Clin Invest,2005,115(3) :747-754.
2Dakhama A, Park JW, Taube C, et al. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production [J]. J Immunol, 2005,175 (3) : 1876-1883.
3Lukacs NW, Moore ML, Rudd BD, et al. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus [J]. Am J Pathol,2006,169(3):977-986.
4John AE, Gerard C J, SchaUer M, et al. Respiratory syncytial virus-induced exaggeration of allergic airway disease is dependent upon CCRl-associated immune responses [J]. Eur J Immunol,2005,35(1 ) : 108-116.
5Park JW, Taube C, Yang ES, et al. Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen [J]. J Allergy Clin Immunol, 2003,112(6) : 1078-1087.
6Doucet C, Brouty-Boye D, Pottin-Clemenceau C, et al. Interleukin(IL)4 and IL-13 act on human lung fibroblasts. Implication in asthma [J ]. J Clin Invest, 1998,101 (10) :2129-2139.
7Rutkowski R, Moniuszko T. Cytokines in allergic inflammatory process [J]. Postepy Hig Med Dosw,2001,55(4): 587-603.
8Dakhama A, Park JW, Taube C, et aL The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production [J]. J Immunol,2005,175(3) : 1876-1883.
9Webb DC, Mckenzie AN, Matthaei KI, et al. Distinct spatial requirement for eosinophil-induced airways hyperreactivity [J]. Immunol Cell Biol,2001,79(2):165-169.
10Lukacs NW, Tekkanat KK, Berlin A, et al. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms [J]. J Immunol,2001,167(2) : 1060-1065.